**Core Concept**
Caplacizumab is a monoclonal antibody fragment that inhibits von Willebrand factor (VWF) binding to platelets, thereby preventing platelet-mediated thrombus formation. This mechanism of action is crucial in the treatment of thrombotic thrombocytopenic purpura (TTP).

**Why the Correct Answer is Right**
Caplacizumab targets the ultra-large VWF multimers, which are responsible for platelet aggregation and thrombus formation in TTP. By inhibiting the binding of VWF to platelets, caplacizumab reduces platelet activation and aggregation, thereby preventing the formation of thrombi in small blood vessels. This mechanism is particularly effective in TTP, where the ultra-large VWF multimers are highly elevated.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because caplacizumab is not used to treat conditions involving platelet aggregation, such as acute coronary syndromes or stroke, where anticoagulants like heparin or aspirin are more commonly used.
**Option B:** This option is incorrect because caplacizumab is not used to treat conditions involving immune-mediated platelet destruction, such as immune thrombocytopenic purpura (ITP), where corticosteroids or immunosuppressive agents are more commonly used.
**Option C:** This option is incorrect because caplacizumab is not used to treat conditions involving coagulation factor deficiencies, such as hemophilia A or B, where factor replacement therapy is more commonly used.
**Option D:** This option is incorrect because caplacizumab is not used to treat conditions involving vascular inflammation, such as vasculitis, where immunosuppressive agents or anticoagulants are more commonly used.

**Clinical Pearl / High-Yield Fact**
Caplacizumab is the first monoclonal antibody fragment approved for the treatment of TTP, and its use has been shown to improve outcomes in patients with this condition by reducing the risk of thrombotic events.

**Correct Answer: B. Thrombotic thrombocytopenic purpura (TTP).**